{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:33:06Z","timestamp":1792783986799,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006418","name":"Brown University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006418","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/05gq02987","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.esmorw.2026.100779","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:46:56Z","timestamp":1789483616000},"page":"100779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical and genomic determinants of early treatment discontinuation in non-small-cell lung cancer: an analysis of the AACR Project GENIE Biopharma Collaborative NSCLC dataset"],"prefix":"10.1016","volume":"14","author":[{"given":"D.","family":"Hamze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mohsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Minuit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4068-7153","authenticated-orcid":false,"given":"E.D.","family":"Gamsiz Uzun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2851-7242","authenticated-orcid":false,"given":"J.L.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmorw.2026.100779_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmorw.2026.100779_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1417175","article-title":"Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis","volume":"14","author":"McKinley","year":"2024","journal-title":"Front Oncol"},{"issue":"28","key":"10.1016\/j.esmorw.2026.100779_bib3","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.22.00825","article-title":"Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO Living Guideline","volume":"40","author":"Singh","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100779_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100779_bib5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00262-021-03045-9","article-title":"Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1\/PD-L1 checkpoint inhibitors leading to treatment discontinuation","volume":"71","author":"Russano","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"10.1016\/j.esmorw.2026.100779_bib6","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoncol.2023.1891","article-title":"Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer","volume":"9","author":"Sun","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmorw.2026.100779_bib7","article-title":"Collaborating across sectors in service of open science, precision oncology, and patients: an overview of the AACR Project GENIE (Genomics Evidence Neoplasia Information Exchange) Biopharma Collaborative (BPC)","volume":"7","author":"Acebedo","year":"2025","journal-title":"ESMO Real World Data Digit Oncol"},{"issue":"8","key":"10.1016\/j.esmorw.2026.100779_bib8","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.esmorw.2026.100779_bib9","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/2159-8290.CD-21-1547","article-title":"AACR Project GENIE: 100,000 cases and beyond","volume":"12","author":"Pugh","year":"2022","journal-title":"Cancer Discov"},{"issue":"17","key":"10.1016\/j.esmorw.2026.100779_bib10","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1158\/1078-0432.CCR-23-0580","article-title":"The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer","volume":"29","author":"Choudhury","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmorw.2026.100779_bib12","series-title":"Pattern Recognition and Machine Learning","author":"Bishop","year":"2006"},{"key":"10.1016\/j.esmorw.2026.100779_bib13","series-title":"Classification and Regression Trees","author":"Breiman","year":"2017"},{"issue":"8","key":"10.1016\/j.esmorw.2026.100779_bib14","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmorw.2026.100779_bib41","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"30","key":"10.1016\/j.esmorw.2026.100779_bib15","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1200\/JCO.22.00371","article-title":"Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients","volume":"40","author":"Fourie Zirkelbach","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.esmorw.2026.100779_bib16","doi-asserted-by":"crossref","first-page":"E558","DOI":"10.1503\/cmaj.231562","article-title":"Oral targeted therapy for the treatment of non-small cell lung carcinoma","volume":"196","author":"Phillips","year":"2024","journal-title":"CMAJ"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100779_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175679","article-title":"Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: a systematic review of recently published studies","volume":"12","author":"Davies","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100779_bib18","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.annonc.2026.02.008","article-title":"ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours","volume":"37","author":"Saini","year":"2026","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100779_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100779_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa2512071","article-title":"Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC","volume":"394","author":"Fang","year":"2026","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.esmorw.2026.100779_bib21","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.esmorw.2026.100779_bib22","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1001\/jama.2013.4638","article-title":"Medication nonadherence: a diagnosable and treatable medical condition","volume":"309","author":"Marcum","year":"2013","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.esmorw.2026.100779_bib23","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1200\/JCO.2005.05.948","article-title":"A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative","volume":"23","author":"Neuss","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2026.100779_bib25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jpainsymman.2018.08.011","article-title":"Effects of shared decision making on distress and health care utilization among patients with lung cancer: a systematic review","volume":"56","author":"Geerse","year":"2018","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"10.1016\/j.esmorw.2026.100779_bib26","first-page":"153","article-title":"The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment","volume":"68","author":"Carrera","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100779_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41571-022-00700-7","article-title":"Barriers in access to oncology drugs\u2014a global crisis","volume":"20","author":"Barrios","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2026.100779_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/0361198121991497","article-title":"Investigating the role of transportation barriers in cancer patients\u2019 decision making regarding the treatment process","volume":"2675","author":"Etminani-Ghasrodashti","year":"2021","journal-title":"Transp Res Rec"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100779_bib29","first-page":"773","article-title":"The early discontinuation of palliative chemotherapy in older patients with cancer","volume":"22","author":"Kim","year":"2014","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.esmorw.2026.100779_bib30","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1200\/JOP.2012.000543","article-title":"Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer","volume":"8","author":"Aiello Bowles","year":"2012","journal-title":"J Oncol Pract"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100779_bib31","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1186\/s12885-023-11598-4","article-title":"Differences between physician and patient preferences for cancer treatments: a systematic review","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100779_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.35680\/2372-0247.1866","article-title":"Lived experiences of cancer patients who chose to stop receiving treatment","volume":"11","author":"Ali","year":"2024","journal-title":"Patient Exp J"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100779_bib33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/09540120600652303","article-title":"Stigma and social barriers to medication adherence with urban youth living with HIV","volume":"19","author":"Rao","year":"2007","journal-title":"AIDS Care"},{"issue":"suppl 1","key":"10.1016\/j.esmorw.2026.100779_bib34","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0924-9338(15)30881-6","article-title":"Adherence, self-stigma and discontinuation of pharmacotherapy in patients with anxiety disorders: cross-sectional study","volume":"30","author":"Kamaradova","year":"2015","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.esmorw.2026.100779_bib35","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3332\/ecancer.2021.1308","article-title":"Impact of stigma and stigma-focused interventions on screening and treatment outcomes in cancer patients","volume":"15","author":"Akin-Odanye","year":"2021","journal-title":"Ecancermedicalscience"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100779_bib36","article-title":"Getting back on track after treatment of cancer: a qualitative interview study of cancer survivors\u2019 experiences","volume":"20","author":"van der Smissen","year":"2025","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100779_bib37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.esmorw.2026.100779_bib38","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.esmorw.2026.100779_bib39","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.annonc.2021.06.004","article-title":"Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer","volume":"32","author":"Sugawara","year":"2021","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.esmorw.2026.100779_bib40","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:03:12Z","timestamp":1789592592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820126000986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":39,"alternative-id":["S2949820126000986"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100779","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and genomic determinants of early treatment discontinuation in non-small-cell lung cancer: an analysis of the AACR Project GENIE Biopharma Collaborative NSCLC dataset","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100779"}}